| Gail Scully, MD | |
|
119 Belmont St, Worcester, MA 01605-2903 | |
| (508) 856-1720 | |
| Not Available |
| Full Name | Gail Scully |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Infectious Disease |
| Location | 119 Belmont St, Worcester, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083674006 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 238142 (Massachusetts) | Primary |
| Entity Name | Northeast Medical Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235147760 PECOS PAC ID: 2365405024 Enrollment ID: O20050111000265 |
News Archive
Although it is still suggested that acute coronary syndrome patients with first and new-onset depression are at particularly increased risk of worse prognosis, the inconsistent results from the studies included in this systematic review show that there is no consistent evidence to support such statements.
The first, a possible new tax on at least some employer-sponsored health benefits, has support from members of Congress on both sides of the aisle. But during last year's presidential campaign, President Obama spoke out strongly against just such a plan when his opponent, Sen. John McCain suggested it, Roll Call reports.
Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
Federal officials said Monday they're taking a hard look at a new Indiana law that withholds some public funding for Planned Parenthood of Indiana, a development that could cost the state some of its Medicaid funding.
Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gail Scully, MD 85 Herrick Street, Lahey Infectious Disease, Beverly, Beverly, MA 01915 Ph: (978) 816-3100 | Gail Scully, MD 119 Belmont St, Worcester, MA 01605-2903 Ph: (508) 856-1720 |
News Archive
Although it is still suggested that acute coronary syndrome patients with first and new-onset depression are at particularly increased risk of worse prognosis, the inconsistent results from the studies included in this systematic review show that there is no consistent evidence to support such statements.
The first, a possible new tax on at least some employer-sponsored health benefits, has support from members of Congress on both sides of the aisle. But during last year's presidential campaign, President Obama spoke out strongly against just such a plan when his opponent, Sen. John McCain suggested it, Roll Call reports.
Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
Federal officials said Monday they're taking a hard look at a new Indiana law that withholds some public funding for Planned Parenthood of Indiana, a development that could cost the state some of its Medicaid funding.
Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.
› Verified 8 days ago
Dr. Adepeju Gbadebo Champion, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 508-334-2731 Fax: 774-442-4672 | |
Madaiah Lokeshwari, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 123 Summer St, Worcester, MA 01608 Phone: 508-363-6849 | |
Sowmya Korapati, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 508-334-3550 Fax: 774-442-6715 | |
Irma Hashmi, DO Infectious Disease Medicare: Medicare Enrolled Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 508-334-1000 | |
Dr. Madhav Sharma, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 123 Summer St, Worcester, MA 01608 Phone: 508-363-5438 | |
Daniel M Steigman, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 123 Summer Street, Suite 390, Worcester, MA 01608 Phone: 508-368-3120 Fax: 508-368-3121 | |
Dr. Julia D Andrieni, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 55 Lake Ave N, Department Of General Medicine, Worcester, MA 01655 Phone: 508-334-2731 |